Antibe Therapeutics Strengthens Partnering Advisory Team With Appointment of Don Haut

Rhea-AI Summary

Antibe Therapeutics Inc. (TSX: ATE, OTCQB: ATBPF) announced the appointment of Dr. Don Haut to its Partnering Advisory Team. Dr. Haut, previously Chief Business Officer at AskBio, brings extensive experience in business development with over $8 billion in transaction completions. His strategic expertise is expected to enhance Antibe's business capabilities and accelerate partnering activities in 2021. Antibe is focused on developing safer nonsteroidal anti-inflammatory drugs using its unique hydrogen sulfide platform, with lead drug otenaproxesul entering Phase III trials.

Positive

• Dr. Don Haut's appointment is expected to enhance Antibe's business development capabilities.
• Dr. Haut's extensive experience includes completing transactions exceeding $8 billion, which may drive future partnerships.
• Antibe is advancing to Phase III trials for its lead drug, otenaproxesul, indicating progress in drug development.

Negative

• Concerns regarding continuity and the experience gap as Dr. Haut integrates into Antibe's existing team.

Antibe Therapeutics Inc. (TSX: ATE, OTCQB: ATBPF), a clinical stage company leveraging its unique hydrogen sulfide platform to develop safer medicines for pain and inflammation, today announced the appointment of Dr. Don Haut to its Partnering Advisory Team.

“I am delighted to welcome another superstar to our Partnering Advisory Team,” remarked Dan Legault, Antibe’s CEO. “Don’s broad background and tremendous recent success will add new depth to our business development capability as our partnering activities accelerate in 2021.”

Most recently, Dr. Haut was Chief Business Officer of AskBio, a leading clinical stage developer of gene therapies and technologies. He led the firm’s business development activities, completing four transactions in 2020 before taking a leading role in AskBio’s $4 billion acquisition by Bayer AG. In a career spanning academic science, consulting, sales management, and business development, he has completed transactions exceeding $8 billion and been instrumental in multiple product launches. He has also served on the boards of several healthcare companies, including firms involved in joint replacement and repair.

Originally trained as a molecular biologist before joining McKinsey, Dr. Haut has since held senior business roles at 3M Company, Smith & Nephew, and The Medicines Company. More recently, he was Chief Business Officer of Histogenics and Sherlock Biosciences. He earned his PhD in Molecular Biology from the Medical School at the University of Missouri-Columbia and an MBA from Washington University’s Olin School of Business.

Dr. Haut commented, “Antibe’s platform promises a major advance in the treatment of pain and inflammation-based disease. This area is overdue for disruption and represents a massive commercial opportunity. I’m excited to put my shoulder to the wheel to help Antibe fully capture the value of its pipeline as it enters late-stage development.”

About Antibe Therapeutics Inc.

Antibe is leveraging its proprietary hydrogen sulfide platform to develop next-generation, safer nonsteroidal anti-inflammatory drugs (“NSAIDs”) for pain and inflammation arising from a wide range of medical conditions. Antibe is developing three assets that seek to overcome the gastrointestinal (“GI”) ulcers and bleeding associated with NSAIDs. Antibe’s lead drug, otenaproxesul (ATB-346), is entering Phase III for osteoarthritis pain. Additional assets under development include a safer alternative to opioids for peri-operative pain, and a GI-safe alternative to low-dose aspirin. Learn more at antibethera.com.

Forward Looking Information

This news release includes certain forward-looking statements under applicable securities laws, which include, but are not limited to, statements about listing on a senior U.S. exchange, large market partnering and the expansion of strategic opportunities. Any statements contained herein that are not statements of historical facts may be deemed to be forward-looking, including those identified by the expressions "will", "anticipate", "believe", "plan", "estimate", "expect", "intend", "propose", “promises”, “move toward”, “look forward” and similar wording. Forward-looking statements involve known and unknown risks and uncertainties that could cause actual results, performance, or achievements to differ materially from those expressed or implied in this news release. Factors that could cause actual results to differ materially from those anticipated in this news release include, but are not limited to, the Company’s ability to meet all of the quantitative and qualitative listing criteria to list on a US securities exchange; the Company’s ability to successfully arrange large market partnerships; the Company’s ability to capitalize on strategic opportunities; the Company’s ability to capture the full potential of its drug pipeline and platform, and the other risks identified in the Company’s public filings made in Canada. The Company assumes no obligation to update the forward-looking statements or to update the reasons why actual results could differ from those reflected in the forward-looking statements except as required by applicable law.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210107005237/en/

FAQ

Who is Dr. Don Haut and what is his role at Antibe Therapeutics?

Dr. Don Haut has been appointed to Antibe Therapeutics' Partnering Advisory Team, bringing significant business development expertise.

What experience does Dr. Haut bring to Antibe Therapeutics?

Dr. Haut has held multiple senior roles and completed over $8 billion in transactions, including leading AskBio's acquisition by Bayer.

What is the significance of Dr. Haut's appointment for Antibe's future?

His appointment is expected to enhance Antibe's capabilities in business development and accelerate partnerships as they advance their drug pipeline.

What is Antibe's lead drug and its current status?

Antibe's lead drug, otenaproxesul, is entering Phase III trials aimed at addressing osteoarthritis pain.